The Board of Directors has authorized a new share repurchase program allowing the company to buy back up to $500 million of its common stock. Repurchases may be executed at management's discretion through open-market transactions, privately negotiated deals, or accelerated share repurchases, subject to market conditions and applicable securities laws. This initiative signals management's confidence in the company's financial position and long-term growth prospects while maintaining flexibility for other strategic activities. PTC Therapeutics is a global biopharmaceutical company focused on discovering and commercializing treatments for rare genetic disorders.
